Driving Precision Oncology Discovery: How IDT Powers MRD Assessment And Multi-Cancer Detection Research

This content is brought to you by Integrated DNA Technologies, a Danaher Operating Company.

Cancer care is entering a new phase as advances in molecular science reshape how the disease is detected and managed. With more than two million new diagnoses expected annually in the U.S., the need for earlier, more precise intervention has never been greater. Emerging approaches like multi-cancer early detection (MCED) and minimal residual disease (MRD) monitoring are expanding what’s possible, enabling detection of cancers before symptoms appear and identifying lingering disease that traditional methods often miss. At the center of these advances is next-generation sequencing (NGS), which can uncover tiny fragments of circulating tumor DNA in the blood. Together, these innovations are paving the way for more proactive care, more informed treatment decisions, and improved patient outcomes.

Access the full article to examine how these technologies are redefining cancer detection and monitoring.